Details, Fiction and PHA-665752
Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the primary-line remedy of CML-CP. 5 hundred and nineteen individuals with newly diagnosed CML-CP ended up randomly assigned to obtain dasatinib in a dose of 100 mg the moment daily (259 clients) or imatinib at a dose of four hundred mg at th